Ping Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ping Chen has a total of 156 co-authors. Here are the top co-authors by number of shared publications:
Li Yu
Department of Oncology, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, People’s Republic of China
3 shared publicationsXiao Hu
Department of Oncology, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, People’s Republic of China
3 shared publicationsXiaonan Zeng
Department of Oncology, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, People’s Republic of China
3 shared publications- Feng Zhou
State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China
2 shared publications - Guimei Yang
Jiangsu Simcere Pharmaceuticals Co. Ltd, Nanjing, China
2 shared publications Liting Xue
State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Pharmaceuticals Co. Ltd, Nanjing, China
2 shared publications
Latest Publications
- Open Access
- 1 April 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 5489-5508
The Radiosensitizing Effect of Tumor-Derived Microparticles Co-Loaded with Sorafenib and Gold Nanoparticles on Hepatocellular Carcinoma
Objective: Hepatocellular carcinoma (HCC) is a highly heterogeneous tumor with features such as high recurrence, easy metastasis, and poor prognosis, posing significant challenges for clinical treatment. In this study, we introduce a novel approach for treating HCC using tumor cell-derived microparticles (MPs) co-loaded with sorafenib and gold nanoparticles (AuNP) in combination with radiotherapy. Methods: MPSF@AuNP was prepared by co-incubating AuNP with sorafenib, and was evaluated using dynamic light scattering (DLS), transmission electron microscopy (TEM), ultraviolet-visible spectrophotometry (UV-Vis), inductively coupled plasma optical emission spectrometry (ICP-OES), high-performance liquid chromatography (HPLC), and SDS-PAGE electrophoresis. Subsequently, their targeting ability toward hepatocellular carcinoma cells and their combined antitumor therapeutic effects with radiotherapy were investigated through in vitro and in vivo experiments, while their in vivo safety was also assessed. Results: Our results demonstrate that co-loaded microparticles (MPSF@AuNP) can effectively deliver therapeutic agents to tumor cells through homologous targeting, improving the bioavailability of therapeutic drugs and enhancing their cytotoxicity against tumor cells. Furthermore, the combination of MPSF@AuNP with radiotherapy shows a synergistic anti-tumor effect by enhancing the inhibition of tumor cell proliferation, promoting tumor cell apoptosis, remodeling the tumor microenvironment, and activating the anti-tumor immune responses. Conclusion: This study offers a promising treatment approach for malignant tumors such as HCC by using MP co-loaded and delivered with anti-tumor drugs and AuNP in combination with radiotherapy.
- 1 April 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 5489-5508
Open AccessThe Radiosensitizing Effect of Tumor-Derived Microparticles Co-Loaded with Sorafenib and Gold Nanoparticles on Hepatocellular Carcinoma
Objective: Hepatocellular carcinoma (HCC) is a highly heterogeneous tumor with features such as high recurrence, easy metastasis, and poor prognosis, posing significant challenges for clinical treatment. In this study, we introduce a novel approach for treating HCC using tumor cell-derived microparticles (MPs) co-loaded with sorafenib and gold nanoparticles (AuNP) in combination with radiotherapy. Methods: MPSF@AuNP was prepared by co-incubating AuNP with sorafenib, and was evaluated using dynamic light scattering (DLS), transmission electron microscopy (TEM), ultraviolet-visible spectrophotometry (UV-Vis), inductively coupled plasma optical emission spectrometry (ICP-OES), high-performance liquid chromatography (HPLC), and SDS-PAGE electrophoresis. Subsequently, their targeting ability toward hepatocellular carcinoma cells and their combined antitumor therapeutic effects with radiotherapy were investigated through in vitro and in vivo experiments, while their in vivo safety was also assessed. Results: Our results demonstrate that co-loaded microparticles (MPSF@AuNP) can effectively deliver therapeutic agents to tumor cells through homologous targeting, improving the bioavailability of therapeutic drugs and enhancing their cytotoxicity against tumor cells. Furthermore, the combination of MPSF@AuNP with radiotherapy shows a synergistic anti-tumor effect by enhancing the inhibition of tumor cell proliferation, promoting tumor cell apoptosis, remodeling the tumor microenvironment, and activating the anti-tumor immune responses. Conclusion: This study offers a promising treatment approach for malignant tumors such as HCC by using MP co-loaded and delivered with anti-tumor drugs and AuNP in combination with radiotherapy.
- 11 December 2023
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 234, 113704
Advances and challenges in clinical applications of tumor cell-derived extracellular vesicles
- 11 December 2023
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 234, 113704
Advances and challenges in clinical applications of tumor cell-derived extracellular vesicles
- 20 November 2023
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 6 (23) , 21945-21956
Zn-Dipicolylamine-Based ROS-Responsive Bola-Lipid Nanoparticles for Efficient Protein Delivery and Tumor Immunotherapy
- 20 November 2023
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 6 (23) , 21945-21956
Zn-Dipicolylamine-Based ROS-Responsive Bola-Lipid Nanoparticles for Efficient Protein Delivery and Tumor Immunotherapy
- 4 April 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (7_Suppleme) , 1724
Abstract 1724: SCR-8388, a potent and selective SOS1::KRAS inhibitor, is effective in KRAS-addicted cancers
KRAS occurs Mutation in approximately one in seven of all human cancers, making it the most frequently mutated oncogene. The activation of KRAS protein is regulated via switching the cycle between the active form, guanosine- 5′-triphosphate (GTP)-bound state and the inactive form, guanosine-5′-diphosphate (GDP)-bound form. Guanine nucleotide-exchange factors (GEF), including SOS1/2 play a key role in catalyzing the transformation of KRAS from GDP to GTP form. In tumors with dysregulation of the MAPK signal axis, inhibition of SOS1/2 leads to abrogation of the Kras-mediated activation of downstream signals. However, double depletion of SOS1/2 is embryo lethal, and selective inhibition of SOS1 provides a more balanced therapy for Kras mutant tumors. Here we reported SCR-8388 as a highly potent and SOS1- specific inhibitor that effectively inhibited multiple Kras-mutant oncoproteins. SCR-8388 was potently bound to SOS1 and blocked the interaction of KRASG12D-GDP or KRASG12C-GDP with IC50 at single-digit nanomolar level. In contrast, SCR-8388 had no effect on the interaction of KRASG12C-GDP and SOS2. In H358 (KRASG12C) cells, SCR-8388 strongly inhibited the phosphorylation of ERK1/2 with an IC50 of 20 nM. The anti-proliferation activities of SCR-8388 on Kras mutant tumor cell lines were determined using the anchorage-independent three-dimensional (3-D) growth assay. The results showed that SCR-8388 strongly inhibited cell growth in five Kras-mutant cell lines which represent the different Kras mutation genotypes, including G12D, G12C, G12S and G13D mutants, the IC50s ranged from 17 to 120 nM, suggesting the broad activities of SOS1 inhibitor against pan-Kras mutation. In contrast, SCR-8388 (at 1 µM) showed no growth inhibition on two Kras non-addicted cancer cell lines, NCI-H520 and A375. Additionally, SCR-8388 demonstrated enhanced antiproliferation activity in a SOS2 knockout cell line (H358SOS2-/-) in comparison with the parental cells, indicating the high selectivity of SCR-8388 over SOS2. SCR-8388 displayed favorable PK properties, and higher tissue exposure, making SCR-8388 achieve effective tumor growth inhibition. In a subcutaneous MIA PaCa-2 xenograft model, oral administration of SCR-8388 resulted in superior tumor growth control in comparison with the clinical reference. Moreover, the robust anti-tumor efficacy was further observed in another KRASG13D-mutated DLD-1 xenograft model. Furthermore, SCR-8388 exhibited synergistic anti-tumor activity in combination with several MAPK pathway inhibitors, including KRASG12C, MEK, and ERK inhibitors as excepted. Notably, SCR-8388 demonstrated synergistic effects with the anti-EGFR antibody (cetuximab) both in Kras-mutant and WT cell lines in vitro and in vivo. In summary, SCR-8388 is a highly potent and selective SOS1 inhibitor, and effectively inhibits Kras-mutant tumors as mono- or combo therapeutics. Citation Format: Feng Zhou, Guimei Yang, Feng Tang Tang, Yan Zhang, Shengwei Yang, Wenqing Yang, Liting Xue, Ping Chen, Renhong Tang. SCR-8388, a potent and selective SOS1::KRAS inhibitor, is effective in KRAS-addicted cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1724.
- 4 April 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (7_Suppleme) , 1724
Abstract 1724: SCR-8388, a potent and selective SOS1::KRAS inhibitor, is effective in KRAS-addicted cancers
KRAS occurs Mutation in approximately one in seven of all human cancers, making it the most frequently mutated oncogene. The activation of KRAS protein is regulated via switching the cycle between the active form, guanosine- 5′-triphosphate (GTP)-bound state and the inactive form, guanosine-5′-diphosphate (GDP)-bound form. Guanine nucleotide-exchange factors (GEF), including SOS1/2 play a key role in catalyzing the transformation of KRAS from GDP to GTP form. In tumors with dysregulation of the MAPK signal axis, inhibition of SOS1/2 leads to abrogation of the Kras-mediated activation of downstream signals. However, double depletion of SOS1/2 is embryo lethal, and selective inhibition of SOS1 provides a more balanced therapy for Kras mutant tumors. Here we reported SCR-8388 as a highly potent and SOS1- specific inhibitor that effectively inhibited multiple Kras-mutant oncoproteins. SCR-8388 was potently bound to SOS1 and blocked the interaction of KRASG12D-GDP or KRASG12C-GDP with IC50 at single-digit nanomolar level. In contrast, SCR-8388 had no effect on the interaction of KRASG12C-GDP and SOS2. In H358 (KRASG12C) cells, SCR-8388 strongly inhibited the phosphorylation of ERK1/2 with an IC50 of 20 nM. The anti-proliferation activities of SCR-8388 on Kras mutant tumor cell lines were determined using the anchorage-independent three-dimensional (3-D) growth assay. The results showed that SCR-8388 strongly inhibited cell growth in five Kras-mutant cell lines which represent the different Kras mutation genotypes, including G12D, G12C, G12S and G13D mutants, the IC50s ranged from 17 to 120 nM, suggesting the broad activities of SOS1 inhibitor against pan-Kras mutation. In contrast, SCR-8388 (at 1 µM) showed no growth inhibition on two Kras non-addicted cancer cell lines, NCI-H520 and A375. Additionally, SCR-8388 demonstrated enhanced antiproliferation activity in a SOS2 knockout cell line (H358SOS2-/-) in comparison with the parental cells, indicating the high selectivity of SCR-8388 over SOS2. SCR-8388 displayed favorable PK properties, and higher tissue exposure, making SCR-8388 achieve effective tumor growth inhibition. In a subcutaneous MIA PaCa-2 xenograft model, oral administration of SCR-8388 resulted in superior tumor growth control in comparison with the clinical reference. Moreover, the robust anti-tumor efficacy was further observed in another KRASG13D-mutated DLD-1 xenograft model. Furthermore, SCR-8388 exhibited synergistic anti-tumor activity in combination with several MAPK pathway inhibitors, including KRASG12C, MEK, and ERK inhibitors as excepted. Notably, SCR-8388 demonstrated synergistic effects with the anti-EGFR antibody (cetuximab) both in Kras-mutant and WT cell lines in vitro and in vivo. In summary, SCR-8388 is a highly potent and selective SOS1 inhibitor, and effectively inhibits Kras-mutant tumors as mono- or combo therapeutics. Citation Format: Feng Zhou, Guimei Yang, Feng Tang Tang, Yan Zhang, Shengwei Yang, Wenqing Yang, Liting Xue, Ping Chen, Renhong Tang. SCR-8388, a potent and selective SOS1::KRAS inhibitor, is effective in KRAS-addicted cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1724.
- Open Access
- 15 December 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 1071383
Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report
Background: Chemoresistance generally develops in patients with advanced epithelial ovarian cancer, and the prognosis is still very poor, with an expected survival time of less than one year. For this population of individuals, there is currently no standard protocol for clinical benefit.Case presentation: We report a case of an elderly woman diagnosed with stage IIIC high-grade serous ovarian cancer (HGSOC). During a follow-up time of 6 years, the patient initially received multiple sequential courses of chemotherapy with platinum-based regimens and with no maintenance therapy. Similar to most patients with advanced HGSOC, she developed platinum resistance and experienced poor treatment results with a short progression-free survival (PFS). Ultimately, we gave the patient traditional non-platinum-based chemotherapy with bevacizumab and high-dose-rate interstitial brachytherapy followed by olaparib as a maintenance therapy. Up to now, the patient did response well to the treatment, and the PFS had exceeded 12 months.Conclusion: High-dose-rate interstitial brachytherapy combination with PARP inhibitors may be an option for isolated chemoresistant recurrent epithelial ovarian cancer.
- 15 December 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 1071383
Open AccessInterstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report
Background: Chemoresistance generally develops in patients with advanced epithelial ovarian cancer, and the prognosis is still very poor, with an expected survival time of less than one year. For this population of individuals, there is currently no standard protocol for clinical benefit.Case presentation: We report a case of an elderly woman diagnosed with stage IIIC high-grade serous ovarian cancer (HGSOC). During a follow-up time of 6 years, the patient initially received multiple sequential courses of chemotherapy with platinum-based regimens and with no maintenance therapy. Similar to most patients with advanced HGSOC, she developed platinum resistance and experienced poor treatment results with a short progression-free survival (PFS). Ultimately, we gave the patient traditional non-platinum-based chemotherapy with bevacizumab and high-dose-rate interstitial brachytherapy followed by olaparib as a maintenance therapy. Up to now, the patient did response well to the treatment, and the PFS had exceeded 12 months.Conclusion: High-dose-rate interstitial brachytherapy combination with PARP inhibitors may be an option for isolated chemoresistant recurrent epithelial ovarian cancer.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 2675
Abstract 2675: Discovery of potent CNS-penetrant covalent KRAS G12C inhibitors
The RAS family of GTPases, which include KRAS, NRAS, and HRAS, are key regulators of cellular signaling, acting as molecular switches downstream of receptor tyrosine kinases (RTKs) and as key regulators of the RAS/MAPK pathway. RAS cycles between inactive (GDP) and active (GTP) states to regulate the activity of the RAS/MAPK pathway. In many cancers, activating KRAS mutations enable KRAS to persist in the active GTP-bound state, resulting in hyperactive RAS/MAPK pathway signaling that drives cell growth and survival. The KRAS G12C mutation occurs in 14% of lung adenocarcinoma, a cancer type that frequently metastasizes to the brain (40%). To address the high prevalence of KRAS G12C mutant CNS metastases in lung adenocarcinoma, we are developing CNS-penetrant covalent KRAS G12C inhibitors (“ERAS G12Ci’s”) to treat both CNS and systemic disease. ERAS G12Ci’s rapidly form covalent adducts with the KRAS G12C protein in its inactive GDP state and exhibit low nanomolar IC50’s in a nucleotide exchange assay. ERAS G12Ci’s demonstrate high selectivity in a cell-based proteome selectivity assay and inhibit the growth of RAS Initiative KRAS G12C mutant cells, and not RAS Initiative KRAS WT cells. ERAS G12Ci’s potently inhibit cell proliferation in 3-dimensional Cell-Titer Glo (3D-CTG) assays in KRAS G12C mutant lung and pancreatic cell lines (NCI-H1373, NCI-H2122, and MIA PaCa-2). Mechanistically, ERAS G12Ci’s blocked RAS-RAF complex formation and inhibited ERK1/2 phosphorylation. This in vitro activity translates in vivo where ERAS G12Ci’s induce pharmacodynamic modulation in the pancreatic cancer MIA PaCa-2 model. ERAS G12Ci’s significantly inhibit tumor growth in NCI-H1373 and NCI-H2122 CDX lung adenocarcinoma and MIA PaCa-2 PDAC models. No meaningful body weight loss or clinical adverse events were observed with any of these compounds. Human efflux transporter substrate assessments indicate that ERAS G12Ci’s are either not substrates or weak/modest substrates of P-gp, a crucial efflux transporter that can limit CNS penetration. In rat CNS studies, these inhibitors exhibit good CNS penetration performance as measured by brain-to-plasma partition coefficients, which are comparable to those of approved CNS-active small molecule inhibitors. Daily oral administration demonstrates dose-dependent tumor regression in intracranial and intra-carotid injection (ICA) KRAS G12C CDX models. We are optimizing multiple covalent CNS-penetrant KRAS G12C inhibitors that exhibit both CNS and systemic activity in vivo. Citation Format: Jae Hyun Bae, Erin D. Lew, Jun Feng, Marcos Gonzalez-Lopez, Joanne Oh, Patrick Fagan, Matt Salie, Nick Isley, Richard Lam, Adriana Irimia, Robin Nevarez, Bingzhen Lin, Taylor Congdon, Jingchuan Zhang, Dawei Xuan, Ping Chen, Jean-Michel Vernier, Robert Shoemaker. Discovery of potent CNS-penetrant covalent KRAS G12C inhibitors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2675.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 2675
Open AccessAbstract 2675: Discovery of potent CNS-penetrant covalent KRAS G12C inhibitors
The RAS family of GTPases, which include KRAS, NRAS, and HRAS, are key regulators of cellular signaling, acting as molecular switches downstream of receptor tyrosine kinases (RTKs) and as key regulators of the RAS/MAPK pathway. RAS cycles between inactive (GDP) and active (GTP) states to regulate the activity of the RAS/MAPK pathway. In many cancers, activating KRAS mutations enable KRAS to persist in the active GTP-bound state, resulting in hyperactive RAS/MAPK pathway signaling that drives cell growth and survival. The KRAS G12C mutation occurs in 14% of lung adenocarcinoma, a cancer type that frequently metastasizes to the brain (40%). To address the high prevalence of KRAS G12C mutant CNS metastases in lung adenocarcinoma, we are developing CNS-penetrant covalent KRAS G12C inhibitors (“ERAS G12Ci’s”) to treat both CNS and systemic disease. ERAS G12Ci’s rapidly form covalent adducts with the KRAS G12C protein in its inactive GDP state and exhibit low nanomolar IC50’s in a nucleotide exchange assay. ERAS G12Ci’s demonstrate high selectivity in a cell-based proteome selectivity assay and inhibit the growth of RAS Initiative KRAS G12C mutant cells, and not RAS Initiative KRAS WT cells. ERAS G12Ci’s potently inhibit cell proliferation in 3-dimensional Cell-Titer Glo (3D-CTG) assays in KRAS G12C mutant lung and pancreatic cell lines (NCI-H1373, NCI-H2122, and MIA PaCa-2). Mechanistically, ERAS G12Ci’s blocked RAS-RAF complex formation and inhibited ERK1/2 phosphorylation. This in vitro activity translates in vivo where ERAS G12Ci’s induce pharmacodynamic modulation in the pancreatic cancer MIA PaCa-2 model. ERAS G12Ci’s significantly inhibit tumor growth in NCI-H1373 and NCI-H2122 CDX lung adenocarcinoma and MIA PaCa-2 PDAC models. No meaningful body weight loss or clinical adverse events were observed with any of these compounds. Human efflux transporter substrate assessments indicate that ERAS G12Ci’s are either not substrates or weak/modest substrates of P-gp, a crucial efflux transporter that can limit CNS penetration. In rat CNS studies, these inhibitors exhibit good CNS penetration performance as measured by brain-to-plasma partition coefficients, which are comparable to those of approved CNS-active small molecule inhibitors. Daily oral administration demonstrates dose-dependent tumor regression in intracranial and intra-carotid injection (ICA) KRAS G12C CDX models. We are optimizing multiple covalent CNS-penetrant KRAS G12C inhibitors that exhibit both CNS and systemic activity in vivo. Citation Format: Jae Hyun Bae, Erin D. Lew, Jun Feng, Marcos Gonzalez-Lopez, Joanne Oh, Patrick Fagan, Matt Salie, Nick Isley, Richard Lam, Adriana Irimia, Robin Nevarez, Bingzhen Lin, Taylor Congdon, Jingchuan Zhang, Dawei Xuan, Ping Chen, Jean-Michel Vernier, Robert Shoemaker. Discovery of potent CNS-penetrant covalent KRAS G12C inhibitors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2675.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 5441
Abstract 5441: Discovery of a novel RAD51 inhibitor SCR-6992 targeting homologous recombination pathways in cancer
Targeting DNA damage response (DDR) pathways has been proposed as an approach for amplifying tumor-specific replicative lesions. RAD51 plays a central role in the DDR pathway, and thus represents a promising anti-tumor target. We here report the discovery of a series of next generation RAD51 inhibitors that can prevent RAD51 foci formation and particularly, a pre-clinical candidate molecule SCR-6992 with potent anti-tumor efficacies and desirable pre-clinical development drug properties. SCR-6992 exhibits remarkable anti-proliferative potency in human lymphoma Daudi cells in vitro (IC50 = 12 nM) while has no inhibitory effect in normal human cells. The combination of SCR-6992 with chemotherapeutic agents or DDR-targeting drugs produces synergistical anti-cancer response in lymphoma and solid tumor cell lines. Furthermore, SCR-6992 significantly inhibits tumor growth in Daudi xenograft tumor model with the tumor regression observed when dosed orally at 80 mg/kg/day. SCR-6992 also shows acceptable translational drug properties and pharmacokinetic profiles in both rodents and dogs. SCR-6992 was well tolerated in rats and dogs in 14-day dose range finding studies without noted hematological or gastrointestinal toxicities, when dosed up to 200 mg/kg and 40 mg/kg, respectively. Taken together, SCR-6992 demonstrates as an effective RAD51 inhibitor with encouraging anti-tumor activities and favorable development drug properties. The clinical development plans of SCR-6992 have been formulated for hematologic malignancies and solid tumors. Citation Format: Peng Gu, Liting Xue, Ping Chen, Wenjing Li, Ya Geng, Feng Zhou, Guimei Yang, Xiaohong Hou, Chunyan Zhao, Wenqing Yang, Renhong Tang. Discovery of a novel RAD51 inhibitor SCR-6992 targeting homologous recombination pathways in cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5441.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 5441
Open AccessAbstract 5441: Discovery of a novel RAD51 inhibitor SCR-6992 targeting homologous recombination pathways in cancer
Targeting DNA damage response (DDR) pathways has been proposed as an approach for amplifying tumor-specific replicative lesions. RAD51 plays a central role in the DDR pathway, and thus represents a promising anti-tumor target. We here report the discovery of a series of next generation RAD51 inhibitors that can prevent RAD51 foci formation and particularly, a pre-clinical candidate molecule SCR-6992 with potent anti-tumor efficacies and desirable pre-clinical development drug properties. SCR-6992 exhibits remarkable anti-proliferative potency in human lymphoma Daudi cells in vitro (IC50 = 12 nM) while has no inhibitory effect in normal human cells. The combination of SCR-6992 with chemotherapeutic agents or DDR-targeting drugs produces synergistical anti-cancer response in lymphoma and solid tumor cell lines. Furthermore, SCR-6992 significantly inhibits tumor growth in Daudi xenograft tumor model with the tumor regression observed when dosed orally at 80 mg/kg/day. SCR-6992 also shows acceptable translational drug properties and pharmacokinetic profiles in both rodents and dogs. SCR-6992 was well tolerated in rats and dogs in 14-day dose range finding studies without noted hematological or gastrointestinal toxicities, when dosed up to 200 mg/kg and 40 mg/kg, respectively. Taken together, SCR-6992 demonstrates as an effective RAD51 inhibitor with encouraging anti-tumor activities and favorable development drug properties. The clinical development plans of SCR-6992 have been formulated for hematologic malignancies and solid tumors. Citation Format: Peng Gu, Liting Xue, Ping Chen, Wenjing Li, Ya Geng, Feng Zhou, Guimei Yang, Xiaohong Hou, Chunyan Zhao, Wenqing Yang, Renhong Tang. Discovery of a novel RAD51 inhibitor SCR-6992 targeting homologous recombination pathways in cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5441.
- 26 April 2022
- Published by Elsevier in Journal of Food Composition and Analysis
- Vol. 110, 104588
SERS nanosensor of 3-aminobenzeneboronic acid labeled Ag for detecting total arsenic in black tea combined with chemometric algorithms
- 26 April 2022
- Published by Elsevier in Journal of Food Composition and Analysis
- Vol. 110, 104588
SERS nanosensor of 3-aminobenzeneboronic acid labeled Ag for detecting total arsenic in black tea combined with chemometric algorithms
- Open Access
- 5 July 2021
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 40 (1) , 1-2
Correction to: A novel miR-219-SMC4-JAK2/Stat3 regulatory pathway in human hepatocellular carcinoma
- 5 July 2021
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 40 (1) , 1-2
Open AccessCorrection to: A novel miR-219-SMC4-JAK2/Stat3 regulatory pathway in human hepatocellular carcinoma